Genmab A/S
Genmab A/S
0,70 %
1.376,00 DKK
9,50
Kurs
1.376,00
Høj
1.379,00
Ændring
0,70 %
Lav
1.358,50
Opdateret
21-08-2019
Åben
1.367,00
Nyheder om Genmab A/S
Factsheet for Genmab A/S
Company Profile
Description
Genmab is a cancer drug developer, best known for its antibody technology platforms, DuoBody and HexaBody, and its promising first-in-class multiple myeloma drug Darzalex (daratumumab), which is partnered with Johnson & Johnson. The company also has several pipeline candidates targeting other oncologic indications and autoimmune diseases.
Key Stats
Website: http://www.genmab.com
Headquarter country: Denmark
Employees: 157
Market Cap (at close 20-08-2019): DKK 89B
Fiscal Year Ends: december
Stats

Stats 2018 2017 2016 2015 2014
Price/Earnings 46,50 54,90 97,30 125,70 69,00
Forward Price/Earnings 32,40 30,70
Price/Free Cash Flow 113,60 54,60 113,20 8.741,80 618,60
Return on Assets 19,50 18,60 26,00 22,60 13,10
Return on Equity 20,60 19,90 28,60 27,70 22,40
Return on Invested Capital 19,80 19,20 27,80 26,30 19,80
Dividend


Dividend/Share:
Ex. Dividend Date:01-01-0001
Trailing Dividend Yield:
Payout Ratio:0,00
Date Currency Amount
Income Statement

Revenue 2018 2017 2016 2015 2014
Total Revenue 3.025,14 2.365,44 1.816,12 1.133,04 850,39
Gross Profit
Gross Margin %
Operating Expenses 2018 2017 2016 2015 2014
EBITDA 1.700,00 1.136,00 1.171,00 789,00 314,00
Net income 1.472,00 1.104,00 1.187,00 764,00 301,00
Basic Earnings Per Share 24,03 18,14 19,83 13,05 5,35
Operating Income 1,38 1,34 1,05 0,73 0,27
Operating Margin % 45,63% 56,83% 57,97% 64,46% 31,18%
Cash Flow

Cash Flow 2018 2017 2016 2015 2014
Operating Cash Flow 1.015,00 1.589,00 328,00 311,00 133,00
Capital Expenditures -477,00 -89,00 -33,00 -135,00 -75,00
Free Cash Flow 537,00 1.500,00 295,00 176,00 57,00
Balance Sheet

Assets 31-12-2018 31-12-2017 31-12-2016 31-12-2015 31-12-2014
Current Assets 7.433,03 6.059,43 4.897,64 3.667,89 2.766,35 1.692,98
Long Term Assets 1.027,97 543,52 340,60 234,66 100,33 38,54
Total Assets 8.461,00 6.602,94 5.238,24 3.902,55 2.866,68 1.731,53
Liabilities 31-12-2018 31-12-2017 31-12-2016 31-12-2015 31-12-2014
Total Current Liabilities 443,35 327,12 411,54 414,40 655,97 907,50
Long Term Liabilities 3,63 0,00 1,43
Total Liabilities 330,75 411,54 415,83
Equity 31-12-2018 31-12-2017 31-12-2016 31-12-2015 31-12-2014
Retained Earnings -197,46 -1.854,73 -3.106,11 -4.228,28 -5.028,36 -5.357,37
Treasury Stock
Total Stockholder Equity 8.014,36 6.272,19 4.826,70 3.486,72 2.032,94 659,52
Net Tangible Assets 7.544,00 6.147,80 4.644,80 3.294,08 1.970,41 656,98